Spots Global Cancer Trial Database for An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
Official Title: An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa.
Study ID: NCT01898585
Conditions
Interventions
Study Description
Brief Summary: This open-label, single-arm, multicenter study will assess the safety and efficacy of Zelboraf (vemurafenib) in patients with Braf V600 mutation positive metastatic melanoma. Patients will receive Zelboraf 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Hospital; Oncotherapy Dept, Bloemfontein, , South Africa
Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept, Cape Town, , South Africa
Cape Town Oncology Trials, Cape Town, , South Africa
Cancercare, Cape Town, , South Africa
Cancercare, George, , South Africa
Mary Potter Oncology Centre, Groenkloof, , South Africa
Medical Oncology Centre of Rosebank; Oncology, Johannesburg, , South Africa
University of Pretoria; Department of Medical Oncology, Pretoria, , South Africa
Sandton Oncology Medical Group, Sandton, , South Africa
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
